Table 2.
Time on therapy before achieving remission/LDA and before discontinuing csDMARD among bDMARD-naïve and bDMARD-experienced patients
| Time, mean (SD), months | bDMARD-naïve patients | bDMARD-experienced patients | ||
|---|---|---|---|---|
| ETN (n = 146) | Other TNFi (n = 274) | ETN (n = 36) | Other TNFi (n = 161) | |
| Time on TNFi therapy before achieving remission/LDA | 4.8 (5.0) | 6.0 (11.5) | 8.7 (9.2)* | 5.7 (6.8)* |
| Time on csDMARD before achieving remission/LDA | 19.1 (21.4) | 19.7 (22.6) | 27.7 (25.3) | 23.1 (24.8) |
| Time in remission/LDA before discontinuation of csDMARD | 19.0 (25.5) | 15.9 (23.1) | 10.6 (13.3) | 18.4 (26.6) |
| Time on csDMARD before discontinuation of csDMARD | 36.3 (32.7) | 38.6 (32.7) | 41.8 (31.9) | 39.1 (32.3) |
| Time on combination therapy before discontinuation of csDMARD | 23.0 (25.1) | 26.1 (26.9) | 22.8 (18.9) | 21.8 (24.7) |
bDMARD, biologic disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; ETN, etanercept; TNFi, tumor necrosis factor inhibitor
*p < 0.05 for ETN monotherapy versus other TNFi monotherapy